GlassScriptPhysician profile
Prashant R Mudireddy
NPI 1568669661
$4,122.42
in general payments reported to CMS, 2019-2025
21 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $27.20 · 2021: $1,329 · 2022: $735 · 2023: $58.80 · 2024: $378 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,947.64 | 2019-2022 | |
| Abbvie INC. | $601.97 | 2019-2025 | |
| Boston Scientific Corporation | $584.87 | 2019-2025 | Axios, Apollo Esg Nxt System |
| Apollo Endosurgery US INC | $108.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.35 | 2019-2022 | |
| Olympus America INC. | $98.80 | 2019-2025 | Visiglide, Evis Exera III Duodenovideoscope |
| Intercept Pharmaceuticals, INC. | $95.21 | 2021-2025 | |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Medtronic, INC. | $65.42 | 2024 | Nexpowder |
| Cook Medical LLC | $64.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.46 | 2021-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $55.05 | 2022 | |
| Ambu INC. | $48.74 | 2021 | |
| Covidien LP | $32.96 | 2019 | |
| Gilead Sciences, INC. | $31.31 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.59 | 2019-2024 | Dificid |
| Organon LLC | $24.89 | 2024 | |
| Janssen Biotech, INC. | $22.78 | 2022 | |
| Celgene Corporation | $22.33 | 2023 | Zeposia |
| Amgen INC. | $20.58 | 2021 | |
| Redhill Biopharma INC. | $18.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Mudireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.